drugset
Drugs / ChAdOx1 AZD1222
last change Feb 2022 re-read 9 days ago

ChAdOx1 AZD1222

Vaccine

Developed for
COVID-19
Investigated by
Clinixir Co., Ltd. · Mahidol University · Program Management Unit-C (PMU-C), governed by Ministry of Higher Education, Science, Research and Innovation (MHESI)

Trials 1

today NCT05049226 · Ph 2
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05049226 Sep 2021 → Feb 2022 COVID-19 Mahidol University Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ChAdOx1 AZD1222 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05049226 ↗
Modality Vaccine “Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:” NCT05049226 ↗
Route Intramuscular “Administer: Intramuscular (IM) injection in the deltoid muscle” NCT05049226 ↗